DES Mothers (Women who took DES during pregnancy) have an increased risk of breast cancer. Studies suggest that these women have about a 30% higher risk of breast cancer compared to those who were not exposed to DES. This translates to approximately 1 in 6 DES-exposed mothers developing breast cancer over their lifetime, compared to 1 in 8 in the general female population.

This elevated risk appears to continue as DES Mothers age. However, DES exposure has not been linked to significant increases in other cancers or health issues beyond breast cancer. It is recommended that DES Mothers adhere to standard breast cancer screening guidelines and inform their healthcare providers about them.